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12 weeks post-BTM while Group C were sacriﬁced 12 [n = 6], 24 [n = 6]
and 52 [n = 6] weeks post-BTM. At necropsy, both medial compartments
of BTM joints were scored by 2 blinded observers for AC lesions and
osteophytes (OP) using a 0−4 scale. Synovial tissue and a 5mm wide
coronal osteochondral slice were removed from the mid-line of the femur
and tibia and processed for histochemical and histomorphometric analy-
ses using published methods. Intact patellae were used for topographical
biomechanical AC indentation studies.
Results: Gross morphological scores 12 wks post BTM showed a dose-
dependent effect of MPC on AC integrity and OP formation; 100 mil MPC
emerging as the most effective chondroprotective dose relative to HA
alone. Total AC score ratios (HA+MPC)/(HA) showed 100>150>25=10
while OP ratios were 100>25>10>150 mil MPC. Statistically signiﬁcant
(SS) lower scores were observed for total femoral & tibial AC (p = 0.019)
and total AC and OP (p = 0.009) for Group C MPC joints compared HA
alone. Histomorphometric analysis of Group C MPC+HA tibial plateaus
revealed that AC were thicker than the corresponding HA-AC in the middle
(p = 0.057) and outer regions (p = 0.028); for all regions (p = 0.01). The
mean phase lag for the patellae AC of Group C MPC injected joints
was signiﬁcantly lower than the contralateral patella AC (p = 0.002). Mean
modiﬁed Mankin scores for AC sections from Group C MPC+HA joints
were less than corresponding HA sections but were not SS. There was no
evidence of synovial histopathology modulation. The chondroprotective
effects observed for the 100 mil MPC injected joints diminished with time;
the positive effects noted at 12 and 24 weeks BTM being lost by 52 weeks.
Conclusions: This is the ﬁrst report, as far as we are aware, of a
beneﬁcial therapeutic effect of allogenic Stro-3+ MPC on cartilage in-
tegrity in a model of early OA. MPC/MSC are known to release growth
factors and cytokines and also suppress the production of TNF-alpha
by other cells, while up-regulating anti-inﬂammatory cytokines (eg. Il-4,
Il-10). These paracrine activities of MPC could stimulate chondrocyte
biosynthesis of new matrix but also attenuate local production and activity
of catabolic mediators. The ﬁnding in this study that 100 million MPC were
chondroprotective was consistent with such a mechanism of action.
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Purpose: Lubricin is a synovial glycoprotein that supplies a friction-
resistant, anti-adhesive coating to the surfaces of articular cartilage,
thereby protecting against arthritis-associated tissue wear and degrada-
tion. We generated and characterized a novel lubricin protein construct,
“LUB:1”, and evaluated its therapeutic efﬁcacy following intraarticular
delivery in a well-characterized rat model of osteoarthritis (OA).
Methods: An optimized lubricin protein construct (designated “LUB:1”),
containing a truncated mucin-like domain, was expressed in stably trans-
fected CHO cells. Puriﬁed LUB:1 was biochemically characterized and
analyzed ex vivo for its ability to bind to and lubricate cartilage surfaces,
and to prevent cellular adhesion. For in vivo studies (IACUC approved),
unilateral OA was induced in the knees of male Lewis rats (n = 20
animals/treatment group) by transection of the medial collateral ligament
and meniscus (‘meniscal tear’-induced OA). At one week post-surgery,
LUB:1 (20mg/40ml), or phosphate-buffered saline (PBS) vehicle (40ml)
was administered by intraarticular injection, with dosing either once per
week or 3 times per week over a subsequent four week period. At the
end of the studies, tissue sections of each knee joint were analyzed
microscopically and assessed for multiple pathological parameters of OA.
Results: LUB:1 maintains functional N-terminal domains which facili-
tate mutimerization, is appropriately substituted with lubricating O-linked
oligosaccharides, and possesses integral C-terminal domains enabling
binding and localization to cartilage surfaces. LUB:1 is an effective carti-
lage boundary lubricant and inhibitor of cellular adhesion. Local delivery
of LUB:1 was therapeutically effective in preventing cartilage degrada-
tion during the progression of OA. Knee joints from rats treated with
LUB:1 developed signiﬁcantly less severe cartilage damage than PBS
(vehicle)-treated animals, and displayed signiﬁcantly reduced cartilage
degeneration scores (general pathology), total joint scores and cartilage
lesion and degeneration width measurements. Strikingly, the width of
severe cartilage lesions, reﬂecting areas of tibial cartilage damage in
which tissue matrix loss extends through 50% or more of the cartilage
depth, was decreased by 83% in response to LUB:1 administered 3 times
per week. Inhibition of loss of viable matrix further indicated beneﬁcial
effects of LUB:1 on overall cartilage tissue preservation (chondrocytes,
proteoglycan and collagen). Subchondral bone scores did not differ be-
tween treatment groups, indicating that joint loading was comparable in all
animals. Evidence of ﬁbroplasia was not observed in response to LUB:1
treatment, thus supporting a favorable tolerability proﬁle for recombinant
lubricin in the treatment of joint diseases.
Conclusions: Intraarticular supplementation of rat knee joints with LUB:1
resulted in signiﬁcant disease-modifying, chondroprotective effects during
the progression of osteoarthritis, by markedly reducing cartilage degener-
ation and structural damage. The use of recombinant lubricin molecules
is thus indicated for novel biotherapeutic approaches in the treatment of
cartilage pathologies associated with osteoarthritis.
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Purpose: Orchestrated movement of cells in a particular direction to a
speciﬁc location is a central process for tissue development, maintenance
and repair. The understanding of cell migration and chemotactic mech-
anisms may lead to the novel therapeutic strategies for tissue repair or
regeneration. The aim of this study was to identify cytokines and growth
factors that are able to induce migration of human articular chondrocytes
and mesenchymal stem cells (MSCs).
Methods: Isolated normal human articular chondrocytes and human
bone marrow-derived MSCs were used. Chemotaxis assays were per-
formed in modiﬁed Boyden chambers using 48-well microchemotaxis
chamber plates with polycarbonate PVP free membranes with 8-mm
pores.
Growth factors were diluted to appropriate concentrations in DMEM/F12
supplemented with 0.1% FBS, and placed in the lower chamber. Approx-
imately 2×104 cells were allowed to attach to the top wells of the insert.
After 24 h incubation, the migrated cells on the lower side of the inserts
were ﬁxed, stained and counted for 4 random ﬁelds per well under light
microscope at 100× magniﬁcation. The results are expressed as total
number of migrated cells.
Results: Progressive chemotactic effects were observed with increasing
FBS concentrations between 0−20%. Among a series of growth factors
and cytokines tested only PDGF induced a signiﬁcant increase in cell
migration. TGFb, VEGF, IGF-1, Il-8, bFGF, BMP-2, BMP-4 and BMP-7
had no signiﬁcant effects on chondrocytes. The PDGF isoforms AB and
BB were more potent than AA. In human articular chondrocytes there
was a signiﬁcant aging related decline in the ability of cells to migrate
in response to serum and PDGF. MSCs signiﬁcantly responded to FBS
and several factors, including FBS, PDGF, VEGF, IGF-1, Il-8, BMP-4 and
BMP-7.
Conclusions: This study demonstrated that directed cell migration is in-
ducible in human articular chondrocytes and MSC and identiﬁed PDGF as
the most potent chemotactic factor. The present results also demonstrate
an aging-related reduction in the migratory response of human articular
chondrocytes. The ability of human articular chondrocytes to migrate in
response to serum and PDGF, supports the potential of augmenting this
cellular response in cartilage repair and tissue engineering.
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Purpose: Experimental wounding of articular cartilage results in necrotic
and apoptotic chondrocyte death at the lesion edge. Viable cells at the
wound edge are critical for producing a repair tissue capable of integrating
with the native cartilage. The aims of this study were to investigate
whether inhibiting the cell death at the wound edge results in enhanced
integrative cartilage repair.
Methods: Full depth, bovine articular cartilage discs (6mm) were har-
vested from the metacarpophalangeal joint of 7-day old calves. Carti-
lage discs were pre-incubated in media containing inhibitors of necrosis
(Necrostatin-1; 30mM) or apoptosis (Z-VAD-FMK, 20mM) prior to cutting
a central 3mm inner core. This core was left in situ to create disc/ring
composites in order to study cartilage-cartilage integration. Cartilage was
cultured for 2-weeks with the above inhibitors and analysed for necrotic
